Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize
Drugs that sensitize tumour cells to ionizing radiation are prized because they can overcome resistance to radiotherapy. Here, the authors show that anti-tubulin drugs conjugated to cetuximab or trastuzumab can radiosensitize EGFR- or HER2-expressing tumors by increasing DNA damage and cell death du...
Guardado en:
Autores principales: | Stephen R. Adams, Howard C. Yang, Elamprakash N. Savariar, Joe Aguilera, Jessica L. Crisp, Karra A. Jones, Michael A. Whitney, Scott M. Lippman, Ezra E. W. Cohen, Roger Y. Tsien, Sunil J. Advani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/68ca94c8c46f45f584cf14bf29ee56ae |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli,Meysam, et al.
Publicado: (2019) -
Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors.
por: Yoon Sin Oh, et al.
Publicado: (2011) -
Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.
por: Jinming Gu, et al.
Publicado: (2014) -
Increased NRG1-ErbB4 signaling in human symptomatic epilepsy
por: Jun-Ming Zhu, et al.
Publicado: (2017) -
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.
por: Gillian Farnie, et al.
Publicado: (2013)